Treatment of mild hypertension: a five year controlled drug trial. The Oslo study

The American Journal of Medicine
A Helgeland


In 1972--1973, 785 symptom-free men, aged 40 to 49 years, without target organ damage, with systolic blood pressures between 150 and 179 mm Hg and diastolic blood pressure below 110 mm Hg, were assigned at random to one of two groups: (406 to a drug treatment group and 379 to a control group) for a five-year controlled drug treatment trial to evaluate the effect of therapy on cardiovascular complications. Drug treatment started with hydrochlorothiazide. If systolic blood pressure remained above 140 mm Hg and/or diastolic blood pressure above 90 mm Hg, alphamethyldopa was added. If there were side effects, methyldopa was replaced with propranolol. The control group was not given a placebo. The mean observation time was 66 months (range 60 to 78 months). A difference in blood pressure between groups of about 17 mm Hg systolic and 10 mm Hg diastolic was maintained throughout the study. The study protocol had a rather low "ethical" blood pressure roof, 180 mm Hg systolic and/or 110 mm Hg diastolic. Seventeen percent of the control group had an increase in blood pressure above this level during the trial, and drug treatment was started. There was no effect on major cardiovascular morbidity comparing groups as established by randomiz...Continue Reading


Mar 1, 1990·Clinical Cardiology·M LehmannA Schmid
Feb 1, 1990·Journal of Clinical Pharmacology·L M PrisantC G Hames
May 1, 1993·Journal of Clinical Pharmacology·K C Abbott, G Bakris
Jul 31, 1986·The American Journal of Cardiology·P K Whelton, A J Watson
Nov 1, 1980·The American Journal of Medicine·M H Alderman
Jul 1, 1995·Diabetes Research and Clinical Practice·M SekiyaT Kamada
Jan 1, 1989·Social Science & Medicine·M A Edgar, H Schnieden
Jan 1, 1983·Journal of the American College of Cardiology·E D Frohlich
Feb 1, 1983·Journal of the American College of Cardiology·F G Dunn
Nov 1, 2003·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·R A Stein, T L Strickland
Aug 8, 2001·Journal of Evaluation in Clinical Practice·J I Robertson
May 17, 1986·British Medical Journal·L AlfredssonU de Faire
Mar 12, 1988·British Medical Journal·R J Northcote
Jul 31, 1998·BMJ : British Medical Journal·C M Rembold
Jan 1, 1984·Postgraduate Medical Journal·J T Hart
Sep 1, 1985·Postgraduate Medical Journal·J Lowenstein
Sep 7, 2000·Journal of Clinical Pharmacology·R W Piepho, J Beal
Apr 7, 2006·BMC Health Services Research·Fiona CampbellJames M Mason
Sep 1, 1986·American Journal of Public Health·N B ShulmanC G Miles
Jan 1, 1984·International Journal of Health Services : Planning, Administration, Evaluation·S Wing
Jan 1, 1990·Mayo Clinic Proceedings·G L Schwartz
Dec 1, 1989·Mayo Clinic Proceedings·S C Textor
Feb 24, 1998·Mayo Clinic Proceedings·S N Hayes, S J Taler
Sep 26, 1983·The American Journal of Medicine·E D Freis
Oct 1, 1987·American Heart Journal·J P Boissel, P Moleur

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aortic Aneurysm

An aortic aneurysm is the weakening and bulging of the blood vessel wall in the aorta. This causes dilatation of the aorta, which is usually asymptomatic but carries the risk of rupture and hemorrhage. Find the latest research on aortic aneurysms here.

Cardiac Aneurysm

Aneurysm refers to a bulge of the wall or lining of a vessel commonly occurring in the blood vessels at the base of the septum or within the aorta. In the heart, it usually arises from a patch of weakened tissue in a ventricular wall, which swells into a bubble filled with blood. Discover the latest research on cardiac aneurysm here.